POPULATION PHARMACOKINETIC (PK) STUDY OF MULTIPLE DOSES OF CUBICIN® (DAPTOMYCIN) 10 MG/KG IN CRITICAL CARE PATIENTS HAVING BACTEREMIA, ENDOCARDITIS OR SKIN SOFT TISSUE INFECTIONS DUE TO GRAM POSITIVE BACTERIA WITH VARIOUS DEGREES OF RENAL FAILURE: